Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.

Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) is a serine/threonine kinase implicated in the regulation of many biological processes. A fragment-based lead discovery approach was used to generate potent and selective MAP4K4 inhibitors. The fragment hit pursued in this article had excellent ligand efficiency (LE), an important attribute for subsequent successful optimization into drug-like lead compounds. The optimization efforts eventually led us to focus on the pyridopyrimidine series, from which 6-(2-fluoropyridin-4-yl)pyrido[3,2-d]pyrimidin-4-amine (29) was identified. This compound had low nanomolar potency, excellent kinase selectivity, and good in vivo exposure, and demonstrated in vivo pharmacodynamic effects in a human tumor xenograft model.

[1]  Yingyao Zhou,et al.  A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[3]  L. Makings,et al.  A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. , 2002, Assay and drug development technologies.

[4]  Daniel A Erlanson,et al.  Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.

[5]  Karim Bouzakri,et al.  MAP4K4 Gene Silencing in Human Skeletal Muscle Prevents Tumor Necrosis Factor-α-induced Insulin Resistance* , 2007, Journal of Biological Chemistry.

[6]  Ramkumar Veppathur Mohan,et al.  MicroRNA-30d Induces Insulin Transcription Factor MafA and Insulin Production by Targeting Mitogen-activated Protein 4 Kinase 4 (MAP4K4) in Pancreatic β-Cells* , 2012, The Journal of Biological Chemistry.

[7]  J. Srivastava,et al.  The Nck-interacting kinase phosphorylates ERM proteins for formation of lamellipodium by growth factors , 2006, Proceedings of the National Academy of Sciences.

[8]  Kalyani V. P. Guntur,et al.  Tumor Necrosis Factor α (TNFα) Stimulates Map4k4 Expression through TNFα Receptor 1 Signaling to c-Jun and Activating Transcription Factor 2* , 2007, Journal of Biological Chemistry.

[9]  W. Denny,et al.  Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. , 1996, Journal of medicinal chemistry.

[10]  Stanley R Hamilton,et al.  Expression of MAP4K4 Is Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma , 2008, Clinical Cancer Research.

[11]  Xiaoqing Tang,et al.  An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Khatry,et al.  The STE20 Kinase HGK Is Broadly Expressed in Human Tumor Cells and Can Modulate Cellular Transformation, Invasion, and Adhesion , 2003, Molecular and Cellular Biology.

[13]  Cristiano R. W. Guimaraes,et al.  Understanding the Impact of the P-loop Conformation on Kinase Selectivity , 2011, J. Chem. Inf. Model..

[14]  Xiao-Jun Feng,et al.  Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. , 2012, Pathology, research and practice.

[15]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[16]  Anthony M Giannetti,et al.  From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. , 2011, Methods in enzymology.

[17]  P. Nicotera,et al.  Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen , 2008, Cell Death and Differentiation.

[18]  P. Halban,et al.  Silencing Mitogen-activated Protein 4 Kinase 4 (MAP4K4) Protects Beta Cells from Tumor Necrosis Factor-α-induced Decrease of IRS-2 and Inhibition of Glucose-stimulated Insulin Secretion* , 2009, The Journal of Biological Chemistry.

[19]  Harald Mauser,et al.  Chemical Fragment Spaces for de novo Design , 2007, J. Chem. Inf. Model..

[20]  Ming-hua Zhu,et al.  ShRNA-Targeted MAP4K4 Inhibits Hepatocellular Carcinoma Growth , 2010, Clinical Cancer Research.

[21]  P. Furet,et al.  Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.

[22]  Keith L Ligon,et al.  A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. , 2006, Cancer research.

[23]  Norinobu M. Watanabe,et al.  The Ste20 group kinases as regulators of MAP kinase cascades. , 2001, Trends in cell biology.

[24]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[25]  M. Czech,et al.  Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation , 2009, Nature.